Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389363 | PMC |
| http://dx.doi.org/10.1111/ajt.15119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-diabetic therapies on dental implant success in diabetes mellitus: a comprehensive review.
Front Pharmacol
December 2024
Faculty of General Medicine, Yaroslavl State Medical University, Yaroslavl, Russia.
Background And Objective: Dental implant therapy faces challenges in patients with Type 1 and Type 2 Diabetes Mellitus (T1DM and T2DM) due to adverse effects on bone metabolism and immune response. Despite advancements, diabetic patients face higher risks of peri-implantitis and compromised osseointegration. This review assesses the impact of anti-diabetic medications on implant outcomes, offering insights to bridge the gap between animal studies and clinical practice.
View Article and Find Full Text PDFFirst report on QSAR modelling for chemical penetration enhancement ratio (ER) of different FDA-approved drugs in Poloxamer 407: A next step towards better skin permeability of drugs.
Int J Pharm
December 2024
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India. Electronic address:
Poloxamer 407 is a versatile excipient that enhances drug solubilization and prolongs drug release. Poloxamers are non-ionic tri-block copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene. Various researchers have utilized Poloxamer 407 in topical and transdermal drug delivery systems, and it has also been reported to enhance skin permeability.
View Article and Find Full Text PDFExploring the DPP IV inhibitory potential: molecular docking and dynamic simulations of pyridine-3-carboxylic acid and pyrrolidine-2-carboxylic acid analogs.
J Biomol Struct Dyn
December 2024
Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Science and Research, affiliated to SPPU, Pune, India.
Diabetes mellitus remains a global challenge, with Type 2 Diabetes Mellitus (T2DM) prevalence increasing from 4% to 6.4% in the past 30 years. Presently oral hypoglycaemic agents like GLP-1 agonists, biguanides, sulphonylureas, glinides, and thiazolidinediones are employed in clinical practice.
View Article and Find Full Text PDFTreatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro.
Int Immunopharmacol
January 2025
Mucosal Health and Immunology Laboratory (MHIL), Center for Natural and Human Science, Federal University of ABC, Santo André, São Paulo, Brazil; Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil. Electronic address:
Article Synopsis
- Macrophages play a crucial role in regulating the immune response both in normal conditions and during inflammation, and sitagliptin, a diabetes drug, has shown potential anti-inflammatory effects.
- This study investigated how sitagliptin affects macrophage polarization, finding that it enhances the M2 macrophage phenotype while reducing pro-inflammatory markers like TNF-α.
- Additionally, sitagliptin treatment impacted mitochondrial function in M2 macrophages, leading to lower energy production and reduced ability to engulf particles.
Efficacy of Dapagliflozin + Sitagliptin + Metformin Versus Sitagliptin + Metformin in T2DM Inadequately Controlled on Metformin Monotherapy: A Multicentric Randomized Trial.
Adv Ther
December 2024
USV Pvt Ltd, Mumbai, Arvind Vithal Gandhi Chowk, BSD Marg, Station Road, Govandi East, Mumbai, 400 088, India.
Introduction: A slower adoption rate of fixed dose combinations (FDC) in diabetes management is partly due to insufficient data. This study evaluates the safety and efficacy of an FDC of dapagliflozin + sitagliptin + metformin hydrochloride extended release (XR), compared to a dual FDC of sitagliptin + metformin hydrochloride XR among patients with type 2 diabetes mellitus (T2DM) with poor glycemic control when treated with metformin monotherapy.
Methods: A total of 274 patients with T2DM were randomized (1:1) to either arm X, receiving FDC of dapagliflozin (10 mg) + sitagliptin (100 mg) + metformin hydrochloride XR (1000 mg) (Dapa + Sita + Met) tablets, or arm Y, receiving sitagliptin phosphate (100 mg) + metformin hydrochloride XR (1000 mg) (Sita + Met) tablets, and treated for 16 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!